These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16482495)

  • 21. IL-6 and MYC collaborate in plasma cell tumor formation in mice.
    Rutsch S; Neppalli VT; Shin DM; DuBois W; Morse HC; Goldschmidt H; Janz S
    Blood; 2010 Mar; 115(9):1746-54. PubMed ID: 20018915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletional remodeling of c-myc-deregulating chromosomal translocations.
    Kovalchuk AL; Müller JR; Janz S
    Oncogene; 1997 Nov; 15(19):2369-77. PubMed ID: 9393881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
    Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
    Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of a c-myc transgene results in disruption of the mouse Gtf2ird1 gene, the homologue of the human GTF2IRD1 gene hemizygously deleted in Williams-Beuren syndrome.
    Durkin ME; Keck-Waggoner CL; Popescu NC; Thorgeirsson SS
    Genomics; 2001 Apr; 73(1):20-7. PubMed ID: 11352562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
    Smith DP; Bath ML; Harris AW; Cory S
    Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
    Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
    Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal translocations deregulating c-myc are associated with normal immune responses.
    Roschke V; Kopantzev E; Dertzbaugh M; Rudikoff S
    Oncogene; 1997 Jun; 14(25):3011-6. PubMed ID: 9223664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chromosome translocations and the activation of C-myc oncogene in mouse plasmacytomas].
    Ohno S
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):587-96. PubMed ID: 6424577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).
    McDonnell TJ; Korsmeyer SJ
    Nature; 1991 Jan; 349(6306):254-6. PubMed ID: 1987477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AID and Igh switch region-Myc chromosomal translocations.
    Unniraman S; Schatz DG
    DNA Repair (Amst); 2006 Sep; 5(9-10):1259-64. PubMed ID: 16784901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice.
    Janz S
    J Natl Cancer Inst Monogr; 2008; (39):37-40. PubMed ID: 18648000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ig/myc translocations of the plasmacytoma-prone BALB/c strain occur independently of the genetic and parental origin of the affected chromosomes 6, 12, and 15.
    Silva S; Babonits M; Klein G
    Genes Chromosomes Cancer; 1996 Nov; 17(3):179-84. PubMed ID: 8946197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 transgenic mouse model for extraosseous plasmacytoma.
    Kovalchuk AL; Kim JS; Park SS; Coleman AE; Ward JM; Morse HC; Kishimoto T; Potter M; Janz S
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1509-14. PubMed ID: 11805288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus.
    Wiener F; Coleman A; Mock BA; Potter M
    Cancer Res; 1995 Mar; 55(5):1181-8. PubMed ID: 7867005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells.
    Müller JR; Potter M; Janz S
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12066-70. PubMed ID: 7991585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
    Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
    J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue-specific sensitivity to AID expression in transgenic mouse models.
    Rucci F; Cattaneo L; Marrella V; Sacco MG; Sobacchi C; Lucchini F; Nicola S; Della Bella S; Villa ML; Imberti L; Gentili F; Montagna C; Tiveron C; Tatangelo L; Facchetti F; Vezzoni P; Villa A
    Gene; 2006 Aug; 377():150-8. PubMed ID: 16787714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
    Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
    Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on the origins of multiple myeloma and plasmacytomas in mice.
    Potter M
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):211-23. PubMed ID: 1582969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3'
    Kovalchuk AL; Sakai T; Qi CF; Du Bois W; Dunnick WA; Cogné M; Morse HC
    Oncotarget; 2018 Oct; 9(77):34528-34542. PubMed ID: 30349647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.